Compare AstraZeneca plc (AZN) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Suncor Energy Inc. — how do they compare? AstraZeneca plc trades at $168.14 (market cap $253.13B), while Suncor Energy Inc. trades at $60.76 (market cap $71.44B). The key difference: AstraZeneca plc is far larger — about 3.5× Suncor Energy Inc.'s market cap, and Suncor Energy Inc. pays the higher dividend (2.76%). Which is the better fit depends on your goals.
| AZN | SU | |
|---|---|---|
Market Cap | $253.13B | $71.44B |
Sector | Health | Energy |
52-Week High | $209.48 | $69.73 |
52-Week Low | $137.44 | $38.17 |
Enterprise Value | $279.37B | $79.57B |
Dividend Yield | 1.92% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Suncor Energy (SU) trades at $61.27, up 3.41% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 16.54, net margin of 11.62%, and consistent dividend payments. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 slightly missed. Technical indicators signal bullish sentiment with the current price near resistance at $62. Analyst consensus is strongly positive with 74% buy ratings.
SU presents a compelling investment case with attractive valuation metrics and strong profitability. However, investors face risks from oil price volatility and recent operational challenges. The company's disciplined capital allocation and record production support long-term value, but macroeconomic headwinds and competitive pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
